These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Proteolysis of semax analogues with different N-terminal amino acids by aminopeptidases]. Shevchenko KV; V'iunova TV; Nagaev IIu; Andreeva LA; Alfeeva LIu; Miasoedov NF Bioorg Khim; 2011; 37(4):475-82. PubMed ID: 22096989 [TBL] [Abstract][Full Text] [Related]
7. Brain transfer of a new neuromodulating ACTH analog, ebiratide, in rats. Shimura T; Tabata S; Hayashi S Peptides; 1991; 12(3):509-12. PubMed ID: 1681522 [TBL] [Abstract][Full Text] [Related]
8. The behaviorally active peptide ACTH 4-10: measurement in plasma and pharmacokinetics in man. Bickel U; Born J; Fehm HL; Distler M; Voigt KH Eur J Clin Pharmacol; 1988; 35(4):371-7. PubMed ID: 2848706 [TBL] [Abstract][Full Text] [Related]
9. Intranasal application of the melanocortin 4 receptor agonist MSH/ACTH(4-10) in humans causes lipolysis in white adipose tissue. Wellhöner P; Hörster R; Jacobs F; Sayk F; Lehnert H; Dodt C Int J Obes (Lond); 2012 May; 36(5):703-8. PubMed ID: 21629206 [TBL] [Abstract][Full Text] [Related]
10. Sniffing neuropeptides: a transnasal approach to the human brain. Born J; Lange T; Kern W; McGregor GP; Bickel U; Fehm HL Nat Neurosci; 2002 Jun; 5(6):514-6. PubMed ID: 11992114 [No Abstract] [Full Text] [Related]
12. Nasal administration of an ACTH(4-9) peptide analogue with dimethyl-beta-cyclodextrin as an absorption enhancer: pharmacokinetics and dynamics. Schipper NG; Verhoef JC; De Lannoy LM; Romeijn SG; Brakkee JH; Wiegant VM; Gispen WH; Merkus FW Br J Pharmacol; 1993 Dec; 110(4):1335-40. PubMed ID: 8306072 [TBL] [Abstract][Full Text] [Related]
13. In-vivo blood-brain barrier transport of a novel adrenocorticotropic hormone analogue, ebiratide, demonstrated by brain microdialysis and capillary depletion methods. Shimura T; Tabata S; Terasaki T; Deguchi Y; Tsuji A J Pharm Pharmacol; 1992 Jul; 44(7):583-8. PubMed ID: 1357139 [TBL] [Abstract][Full Text] [Related]
14. [An experimental substantiation for using the "Semax" neuroprotector in the treatment of optic-nerve diseases]. Sheremet NL; Polunin GS; Ovchinnikov AN; Kamenskiĭ AA; Levitskaia NG; Andreeva LA; Alfeeva LIu; Nagaev IIu Vestn Oftalmol; 2004; 120(6):25-7. PubMed ID: 15678666 [TBL] [Abstract][Full Text] [Related]
15. Stability of Semax acetyl to proteolysis in various biological media. Shevchenko KV; Nagaev IY; Andreeva LA; Shevchenko VP; Myasoedov NF Dokl Biol Sci; 2013 Mar; 449():110-2. PubMed ID: 23652441 [No Abstract] [Full Text] [Related]
16. Anticoagulant Effects of Arginine-Containing Peptides of the Glyproline Family (His-Phe-Arg-Trp-Pro-Gly-Pro and Thr-Lys-Pro-Arg-Pro-Gly-Pro) Revealed by Thromboelastography. Rogozinskaya EY; Lyapina MG Bull Exp Biol Med; 2017 Dec; 164(2):170-172. PubMed ID: 29181670 [TBL] [Abstract][Full Text] [Related]
17. Susceptibility of ebiratide to proteolysis in rat intestinal fluid and homogenates and its protection by various protease inhibitors. Okagawa T; Fujita T; Murakami M; Yamamoto A; Shimura T; Tabata S; Kondo S; Muranishi S Life Sci; 1994; 55(9):677-83. PubMed ID: 8065230 [TBL] [Abstract][Full Text] [Related]
18. The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo. Dolotov OV; Seredenina TS; Levitskaya NG; Kamensky AA; Andreeva LA; Alfeeva LY; Nagaev IY; Zolotarev YA; Grivennikov IA; Engele Y; Myasoedov NF Dokl Biol Sci; 2003; 391():292-5. PubMed ID: 14556513 [No Abstract] [Full Text] [Related]
19. [Neuroprotective effects of semax in MPTP-induced disturbances of brain dopamine system]. Levitskaia NG; Sebentsova EA; Andreeva LA; Alfeeva LIu; Kamenskiĭ AA; Miasoedov NF Ross Fiziol Zh Im I M Sechenova; 2002 Nov; 88(11):1369-77. PubMed ID: 12587264 [TBL] [Abstract][Full Text] [Related]